Meeting News CoverageVideo

VIDEO: Esbriet reduces mortality in patients with IPF

MONTREAL — Pirfenidone appeared to reduce mortality associated with idiopathic pulmonary fibrosis, as well as all-cause mortality, compared with placebo, according to Steven D. Nathan, MD, FCCP.

Nathan discusses the results of two studies that evaluated mortality after 52, 72, and 120 weeks of Pirfenidone (Esbriet, Genentech), at CHEST Annual Meeting 2015.

MONTREAL — Pirfenidone appeared to reduce mortality associated with idiopathic pulmonary fibrosis, as well as all-cause mortality, compared with placebo, according to Steven D. Nathan, MD, FCCP.

Nathan discusses the results of two studies that evaluated mortality after 52, 72, and 120 weeks of Pirfenidone (Esbriet, Genentech), at CHEST Annual Meeting 2015.

    See more from CHEST Annual Meeting